BCMA CAR-T相关小肠结肠炎中黏膜CAR-T细胞持续存在与炎症重塑
本研究通过单细胞转录组、流式细胞术和组织成像分析CAR-TEC患者(n=10)、无EC的CAR-T治疗对照(n=7)和健康志愿者(n=26)的肠道活检,发现黏膜B细胞和浆细胞耗竭、细胞毒性CAR-T细胞扩增及炎症性髓系、基质和胶质细胞重塑与CAR-TEC相关,JAK抑制(乌帕替尼)在两名患者中带来临床、内镜和组织学改善。
要点
- CAR-TEC以黏膜B细胞/浆细胞耗竭和细胞毒性CAR-T细胞扩增为特征。
- 干扰素-JAK-STAT重编程支持JAK抑制作为机制导向治疗。
- 乌帕替尼在两名CAR-TEC患者中实现临床、内镜和组织学改善。
核心结论
- CAR-TEC是涉及多间室严重黏膜失调的综合征,对B细胞靶向治疗领域有启示。
研究设计与样本
- 采用单细胞转录组学、流式细胞术和组织成像分析肠道活检。
- 纳入CAR-TEC患者(n=10)、无EC的CAR-T治疗对照(n=7)和健康志愿者(n=26)。
主要发现
- CAR-TEC与黏膜B细胞和浆细胞深度耗竭、高细胞毒性CAR-T细胞扩增及炎症性髓系、基质和胶质细胞重塑相关。
- 细胞间通讯分析提示CAR-T治疗对照存在代偿性黏膜状态,而CAR-TEC中可见端细胞驱动的基质龛功能障碍。
- 基质、内皮和上皮间室中观察到干扰素及JAK-STAT相关重编程。
关键数值与推荐
- 两名CAR-TEC患者接受乌帕替尼(口服选择性JAK1抑制剂)后出现临床、内镜和组织学改善。
临床怎么用
- JAK抑制可作为CAR-TEC的合理机制导向治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)-a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell-cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib-an oral selective JAK 1 inhibitor-resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
引用
- Kethidi N, Pothukuchi S, Aleman A, et al. Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy. Nat Med. 2026. PMID: 42778764. doi:10.1038/s41591-026-04632-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。